Agios Pharmaceuticals Stock Rises on FDA Acceptance of Mitapivat Supplemental NDA
Shares in Agios Pharmaceuticals surged over 14% after the FDA accepted its supplemental New Drug Application (NDA) for mitapivat to treat sickle cell disease with a Priority Review, setting an action date by November 1. Although the drug did not meet one primary endpoint related to pain crises reduction, it showed positive results in other key endpoints.
Tickers: $AGIO